What is the appropriate gabapentin dosing for neuropathic pain in a patient with an eGFR of 13–16 mL/min/1.73 m²?

Gabapentin Dosing for Neuropathic Pain in Severe Renal Impairment (eGFR 13-16)

For a patient with eGFR 13-16 mL/min, start gabapentin at 100-150 mg once daily and titrate cautiously to a maximum of 200-300 mg once daily, with supplemental doses of 125-150 mg after each hemodialysis session if the patient is on dialysis 1.

Renal Dose Adjustment Algorithm

The FDA-approved dosing table provides explicit guidance for severe renal impairment 1:

• eGFR 15 mL/min (closest match to 13-16 range):

  • Starting dose: 100 mg once daily
  • Titration options: 125 mg, 150 mg, 200 mg, or 300 mg once daily
  • Maximum: 300 mg once daily

• For eGFR <15 mL/min: Reduce the daily dose proportionally to creatinine clearance. Since your patient has eGFR 13-16, which is at or just below 15, use the 15 mL/min dosing regimen as the ceiling, potentially reducing further based on clinical response.

Hemodialysis Considerations

If your patient is on hemodialysis 1:

• Maintain the base dose according to the eGFR 15 schedule (100-300 mg once daily)
• Add supplemental post-hemodialysis doses: 125-150 mg after each 4-hour dialysis session
• These supplemental doses compensate for drug removal during dialysis

Critical Dosing Principles

The standard neuropathic pain doses (1800-3600 mg/day) used in patients with normal renal function are completely inappropriate for your patient 2, 1. Gabapentin is renally eliminated, and failure to adjust for severe renal impairment risks:

• Severe sedation and dizziness
• Respiratory depression
• Altered mental status
• Drug accumulation with toxicity

Titration Strategy

1. Week 1-2: Start 100 mg once daily at bedtime (minimizes sedation)
2. Week 3-4: If tolerated and pain persists, increase to 150 mg once daily
3. Week 5-6: Consider 200 mg once daily if needed
4. Maximum: 300 mg once daily (rarely needed and increases adverse effects)

The guideline recommendation to "reduce if impaired renal function" 2 is operationalized through the FDA dosing table, which shows that severe renal impairment requires 90-95% dose reduction compared to standard dosing.

Monitoring Requirements

• Assess pain relief weekly during titration (adequate trial requires 3-8 weeks at stable dose) 2
• Monitor for dose-dependent adverse effects: dizziness, sedation, peripheral edema 2
• Recheck renal function if clinical status changes, as further deterioration requires additional dose reduction 1

Alternative Consideration

Given the severe dosing limitations with gabapentin in this renal function range, pregabalin may offer no advantage as it also requires substantial renal dose adjustment 2. Consider discussing with nephrology whether the patient's pain condition might be better managed with non-renally eliminated alternatives (e.g., topical lidocaine for localized neuropathic pain, or duloxetine if no contraindications) 2, 3.

Common Pitfall to Avoid

Do not use the standard starting dose of 300 mg three times daily 2 recommended for patients with normal renal function. This would result in a 9-fold overdose and likely cause severe toxicity in your patient with eGFR 13-16. Always calculate creatinine clearance and adjust accordingly 1.